Efficacy and predictor of anti-TNFα agents in patients with intestinal Behçet's disease
dc.contributor.author | Miyazaki, Haruka | |
dc.contributor.author | Watanabe, Daisuke | |
dc.contributor.author | Okamoto, Norihiro | |
dc.contributor.author | Tokunaga, Eri | |
dc.contributor.author | Ku, Yuna | |
dc.contributor.author | Takenaka, Haruka | |
dc.contributor.author | Hoshi, Namiko | |
dc.contributor.author | Ooi, Makoto | |
dc.contributor.author | Kodama, Yuzo | |
dc.date.accessioned | 2022-08-10T18:10:56Z | |
dc.date.available | 2022-08-10T18:10:56Z | |
dc.date.issued | 2022-03-28 | |
dc.identifier.citation | BMC Gastroenterology. 2022 Mar 28;22(1):149 | |
dc.identifier.uri | https://doi.org/10.1186/s12876-022-02221-0 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/173563 | en |
dc.description.abstract | Abstract Background Behçet’s disease (BD) is a recurrent multisystem inflammatory disease. Anti-tumor necrosis factor (TNF) α agents have been used to treat patients with intestinal BD with severe disease activity or those who are resistant to conventional treatments; however, the long-term efficacy of anti-TNFα agents in intestinal BD remains unclear. In the present study, we investigated the clinical outcomes and predictors of discontinuation of anti-TNFα agents in patients with intestinal BD. Methods We reviewed the medical records of patients with intestinal BD who received first-line anti-TNFα agents between January 2009 and June 2020. The primary outcome was the percentage of patients who continued anti-TNFα therapy for 48 weeks. Secondary outcomes included the percentage of patients who achieved marked improvement, complete remission, and mucosal healing, as well as predictors of discontinuation of anti-TNFα agents. Results A total of 29 patients were included in the study. Twenty-two (75.9%) patients continued anti-TNFα therapy for 48 weeks. The percentage of patients who achieved marked improvement, complete remission, and mucosal healing at week 48 was 48.3%, 37.9%, and 48.3%, respectively. At week 96, 11 (37.9%) patients achieved marked improvement, complete remission, and mucosal healing. A higher C-reactive protein level (CRP; ≥ 1 mg/dL) at baseline was a predictor of discontinuation of anti-TNFα agents. Conclusions The 48-week continuation rate of anti-TNFα agents was 75.9% in bio-naïve patients with intestinal BD. However, a higher baseline CRP level (≥ 1 mg/dL) was associated with discontinuation of anti-TNFα agents. | |
dc.title | Efficacy and predictor of anti-TNFα agents in patients with intestinal Behçet's disease | |
dc.type | Journal Article | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/173563/1/12876_2022_Article_2221.pdf | |
dc.identifier.doi | https://dx.doi.org/10.7302/5294 | |
dc.language.rfc3066 | en | |
dc.rights.holder | The Author(s) | |
dc.date.updated | 2022-08-10T18:10:55Z | |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.